Liquidia Technologies, Inc. (LQDA) News
Filter LQDA News Items
LQDA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LQDA News Highlights
- LQDA's 30 day story count now stands at 9.
- Over the past 18 days, the trend for LQDA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about LQDA are DEC and BIRD.
Latest LQDA News From Around the Web
Below are the latest news stories about LIQUIDIA CORP that investors may wish to consider to help them evaluate LQDA as an investment opportunity.
Biotech CEOs Are Buying Up Their Surging StocksShares of Cibus, OmniAb, and Liquidia—three small biotechs—have seen big gains this year. Their CEOs just bought more stock. |
Peabody Energy, Janus International, and More Stocks See Action From Activist InvestorsActivists file with the SEC on Liquidia, Janus International Group, Peabody Energy, Disc Medicine, and Blue Bird. |
Industry Analysts Just Upgraded Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts By 38%Liquidia Corporation ( NASDAQ:LQDA ) shareholders will have a reason to smile today, with the analysts making... |
Independent Director of Liquidia Picks Up 5.3% More StockThose following along with Liquidia Corporation ( NASDAQ:LQDA ) will no doubt be intrigued by the recent purchase of... |
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) today affirmed the earlier decision by the Patent Trial and Appeal Board (PTAB) which found all claims of U.S. Patent No. 10,716 |
Insider Sell Alert: Chief Medical Officer Rajeev Saggar Sells 14,887 Shares of Liquidia Corp (LQDA)Liquidia Corp (NASDAQ:LQDA), a company at the forefront of developing and commercializing products in the field of pulmonary arterial hypertension and other applications of its PRINT technology, has recently witnessed a significant insider transaction. |
Liquidia Announces Pricing of Public Offering of Common StockMORRISVILLE, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16 for total gross proceeds of approximately $25.0 million, before deducting underwriting discounts and commissions and expenses payable by Liquidia. The offering is expected to close on December 14, 2023, subject to customary closing conditions. BofA Securities acted as the |
Liquidia (NASDAQ:LQDA) shareholders have earned a 35% CAGR over the last three yearsThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can... |
Liquidia Corporation (NASDAQ:LQDA) Q3 2023 Earnings Call TranscriptLiquidia Corporation (NASDAQ:LQDA) Q3 2023 Earnings Call Transcript November 7, 2023 Liquidia Corporation misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $-0.2. Operator: Good morning, and welcome everyone to the Liquidia Corporation Third Quarter 2023 Financial Results and Corporate Update Conference Call. My name is Therese [ph], and I will be your […] |
Q3 2023 Liquidia Corp Earnings CallQ3 2023 Liquidia Corp Earnings Call |